deltatrials
Completed PHASE3 INTERVENTIONAL 1-arm NCT01421069

Extension Study Evaluating Etanercept in 3 Subtypes of Childhood Arthritis (CLIPPER2)

AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND CLINICAL BENEFIT OF ETANERCEPT IN CHILDREN AND ADOLESCENTS WITH EXTENDED OLIGOARTICULAR JUVENILE IDIOPATHIC ARTHRITIS, ENTHESITIS-RELATED ARTHRITIS, OR PSORIATIC ARTHRITIS WHO WERE PREVIOUSLY ENROLLED IN PROTOCOL 0881A1-3338-WW(B1801014)

Sponsor: Pfizer

Conditions Juvenile Idiopahtic Arthritis
Interventions etanercept
Updated 17 times since 2017 Last updated: Apr 6, 2022 Started: Oct 10, 2011 Primary completion: Feb 4, 2021 Completion: Feb 4, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01421069, this PHASE3 trial focuses on Juvenile Idiopahtic Arthritis and remains completed. Sponsored by Pfizer, it has been updated 17 times since 2011, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Mar 2017 · 28 days · monthly snapshot~Mar 2017 – ~Jun 2017 · 3 months · monthly snapshot~Jun 2017 – ~Sep 2017 · 3 months · monthly snapshot~Sep 2017 – ~Dec 2017 · 3 months · monthly snapshot~Dec 2017 – ~Jun 2018 · 6 months · monthly snapshot~Jun 2018 – ~Mar 2019 · 9 months · monthly snapshot~Mar 2019 – ~Mar 2020 · 12 months · monthly snapshot~Mar 2020 – ~Jan 2021 · 10 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~May 2021 · 2 months · monthly snapshot~May 2021 – ~Dec 2022 · 19 months · monthly snapshot~Dec 2022 – ~Jul 2024 · 19 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – ~Oct 2025 · 30 days · monthly snapshot~Oct 2025 – present · 9 months · monthly snapshot

Change History

17 versions recorded

  1. Oct 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2025 — Oct 2025 [monthly]

    Completed PHASE3

  3. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  5. Dec 2022 — Jul 2024 [monthly]

    Completed PHASE3

▶ Show 12 earlier versions

  1. May 2021 — Dec 2022 [monthly]

    Completed PHASE3

  2. Mar 2021 — May 2021 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  3. Jan 2021 — Mar 2021 [monthly]

    Active Not Recruiting PHASE3

  4. Mar 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE3

  5. Mar 2019 — Mar 2020 [monthly]

    Active Not Recruiting PHASE3

  6. Jun 2018 — Mar 2019 [monthly]

    Active Not Recruiting PHASE3

  7. Dec 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE3

  8. Sep 2017 — Dec 2017 [monthly]

    Active Not Recruiting PHASE3

  9. Jun 2017 — Sep 2017 [monthly]

    Active Not Recruiting PHASE3

  10. Mar 2017 — Jun 2017 [monthly]

    Active Not Recruiting PHASE3

  11. Feb 2017 — Mar 2017 [monthly]

    Active Not Recruiting PHASE3

  12. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE3

    First recorded

Oct 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Pfizer
Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Belgrade, Serbia , Berlin, Germany , Bremen, Germany , Brno, Czechia , Brussels, Belgium , Bucaramanga, Colombia , Budapest, Hungary , Bydgoszcz, Poland , Chieti Scalo, Italy , Esplugues de Llobregat, Spain and 22 more locations